Attana has received an order for contract research from an American biotech company.

The contract is related to interaction characterization of therapeutic antibodies using Attana’s cell-based technology. The order value is approximately 300 kSEK and will have a positive effect of the cash flow and results during Q3 2018.

Attana’s application specialists will perform interaction analysis assays. The interaction between a specific target receptor in the cell membrane and a number of potential therapeutic antibodies will be detailed characterized with respect to interactions kinetics and affinity. The results might be used for selecting and optimize the most suitable antibodies for further drug development.